Answers are grounded in this paper and cite their sources.
Demonstrates improved blood-brain barrier opening in mice using ultrasound and nanodroplets, suggesting safer therapy delivery methods.
Focused ultrasound (FUS) combined with decafluorobutane (DFB) nanodroplets (NDs) have enabled sub-millimeter blood–brain barrier opening (BBBO). However, acoustic droplet vaporization (ADV) of DFB NDs requires high acoustic pressures, increasing off-target risk. We hypothesized that mixing DFB with lower-boiling octafluoropropane (OFP) would reduce AVD thresholds to facilitate safer more precise sub-focal BBBO. NDs containing 20–80% OFP/DFB mole ratios (n = 3) were exposed to FUS (1 MHz, 0.4–4.3 MPa) in vitro and ADV thresholds detirmined. Passive cavitation detection (PCD) results confirmed OFP/DFB mixtures, independent of OFP ratio, vaporized at peak negative pressures (PNP) significantly lower than pure DFB (p < 0.005). In vivo, C57BL/6 mice (n = 6) received FUS (1.5 MHz, 700 kPa) with 50/50 mixture NDs. Contrast-enhanced T1-weighted MRI revealed axial BBBO areas significantly smaller than the theoretical −6 dB focal region (395±287 μm, p < 0.0001), confirming sub-focal bioeffects. In an ongoing study, CDF rats received escalating FUS intensities (1.1 MHz, 0.5–1.8 MPa; n = 9/PNP) after administration of DFB or 50/50 mixture NDs. Preliminary PCD and histological analyses reinforce mixture NDs require reduced PNPs to achieve BBBO and both formulations produced pressure-dependent sub-focal Evans blue extravasation. Our results indicate that OFP/DFB NDs vaporize at lower PNPs, enabling reproducible sub-focal BBBO. This approach enhances the precision and safety of FUS-mediated delivery for targeted therapies in discrete brain regions.
No takes yet. Share an insight, caveat, or question.
Mattern et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: